CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new classes of antiretroviral drugs that target specific interactions between the HIV virus and human host cells. By inhibiting host factors critical for HIV replication, the project aims to create more effective treatments that are less susceptible to resistance.
Highly active antiretroviral therapy is effective at controlling HIV-1 replication, however emergence and transmission of drug-resistant viruses is increasing, including viruses resistant to the newly developped integrase catalytic inhibitors.
It is essential that new antiretrovirals (ARVs) become available.
Most ARVs in development belong to the classes of viral enzyme inhibitors.
Since HIV requires cellular cofactors for its replication cycle, we aim to develop novel classes of ARVs inhibiting…
LABORATOIRE BIODIM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Amsterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
